Ladenburg downgraded Acrivon Therapeutics to Neutral from Buy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics price target raised to $25 from $18 at BMO Capital
- Acrivon Therapeutics price target lowered to $22 from $26 at JonesResearch
- Acrivon Therapeutics Inc trading resumes
- Acrivon Therapeutics Inc trading halted, volatility trading pause
- Acrivon Therapeutics price target raised to $30 from $26 at Piper Sandler